MW-150

• Product Name Alternative:

  MW01-18-150SRM

• UNSPSC Description:

  MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. MW-150 inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia[1].

• Target Antigen:

  Autophagy; p38 MAPK

• Type:

  Reference compound

• Related Pathways:

  Autophagy;MAPK/ERK Pathway

• Field of Research:

  Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/mw-150.html

• Purity:

  99.89

• Solubility:

  DMSO : 40 mg/mL (ultrasonic)

• Smiles:

  CN1CCN(C2=NN=C(C3=CC=C4C=CC=CC4=C3)C(C5=CC=NC=C5)=C2)CC1

• Molecular Weight:

  381.47

• References & Citations:

  [1]Roy SM, et al. Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models. ACS Chem Neurosci. 2015 Apr 15;6(4):666-80.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 2

• CAS Number:

  1628502-91-9